novo nordisk zepbound - Search News

News

Novo Nordisk to Replace C.E.O.

CNBC on MSN · 20h

Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges

The New York Times · 3d

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.

Pharmaceutical Technology on M… · 1d

Novo Nordisk’s CEO to step down as weight loss market share plummets

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor agonists (GLP-1RA) market pressure from Eli Lilly.

2h

Novo Nordisk and US biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Zepbound More Effective for Weight Loss Than Wegovy, Eli Lilly Trial Shows

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

3d

Novo Nordisk Stock: Seems Like A No-Brainer At These Levels

Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...

7don MSN

Here’s how much extra weight is lost with Zepbound over Wegovy

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

1d

Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns

Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...

3d

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Fierce Biotech6d

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results